These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34253649)

  • 1. LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial.
    Mucke J; Kuss O; Brinks R; Schanze S; Schneider M
    Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.
    Golder V; Kandane-Rathnayake R; Li N; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Goldblatt F; Oon S; O'Neill S; Ng K; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Lau CS; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2024 Aug; 6(8):e528-e536. PubMed ID: 38876129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study.
    Golder V; Kandane-Rathnayake R; Huq M; Nim HT; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2019 Oct; 1(2):e95-e102. PubMed ID: 38229349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
    Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
    Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting lupus low disease activity state and remission in SLE: novel insights.
    Gao D; Hao Y; Fan Y; Ji L; Zhang Z
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1083-1089. PubMed ID: 34392757
    [No Abstract]   [Full Text] [Related]  

  • 9. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
    Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Yu D; Karyekar CS; Sing Lau C; Monk JA; Nikpour M; Hoi A; Morand EF;
    Lancet Rheumatol; 2022 Dec; 4(12):e822-e830. PubMed ID: 38261390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.
    Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Medina M; Elera-Fitzcarrald C; Zevallos F; Pastor-Asurza CA; Lofland J; Zazzetti F; Karyekar CS; Alarcón GS; Perich-Campos RA
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.
    Piga M; Floris A; Cappellazzo G; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Res Ther; 2017 Nov; 19(1):247. PubMed ID: 29126432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
    Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.
    Na Nakorn K; Piyaphanee N; Sukharomana M; Pinpatanapong R; Charuvanij S
    Clin Rheumatol; 2023 Jun; 42(6):1655-1664. PubMed ID: 36780064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort.
    Hao Y; Oon S; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Morand EF; Nikpour M; Zhang Z
    Clin Rheumatol; 2022 Feb; 41(2):357-366. PubMed ID: 34595670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus.
    Sharma C; Raymond W; Eilertsen G; Nossent J
    Arthritis Care Res (Hoboken); 2020 Mar; 72(3):447-451. PubMed ID: 30821926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting DORIS Remission and LLDAS in SLE: A Review.
    Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
    Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study.
    Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R
    Arthritis Res Ther; 2020 Jan; 22(1):8. PubMed ID: 31924267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
    Pitsigavdaki S; Nikoloudaki M; Garantziotis P; Silvagni E; Repa A; Marangoni A; Flouri I; Avgoustidis N; Parperis K; Fanouriakis A; Govoni M; Sidiropoulos P; Boumpas DT; Bortoluzzi A; Bertsias G
    Ann Rheum Dis; 2024 Mar; 83(4):464-474. PubMed ID: 38233103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.
    Kandane-Rathnayake R; Louthrenoo W; Hoi A; Luo SF; Wu YJ; Chen YH; Cho J; Lateef A; Hamijoyo L; Navarra SV; Zamora L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Hao Y; Zhang Z; Kikuchi J; Takeuchi T; Basnayake BMDB; Chan M; Ng KPL; Tugnet N; Kumar S; Oon S; Goldblatt F; O'Neill S; Gibson KA; Ohkubo N; Tanaka Y; Bae SC; Lau CS; Nikpour M; Golder V; Morand EF;
    Arthritis Res Ther; 2022 Mar; 24(1):70. PubMed ID: 35287720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.